Compared to MPN-CP, sAML patients were more likely to harbor variants in chromatin remodelers and epigenetic modifiers, TP53, Serine and Arginine Rich Splicing Factor 2 (SRSF2), transcription factors (i.e., RUNX1, CUX1, GATA2, IKZF1) and signal transduction genes (i.e., NRAS, KRAS, PTPN11, FLT3) (Figure 2C). This evidence concerns the gene PTPN11 and myeloproliferative neoplasm.